Literature DB >> 23737601

Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.

Ping Qiu1, Yan Li, Joseph Shiloach, Xizhong Cui, Junfeng Sun, Loc Trinh, Joanna Kubler-Kielb, Evgeny Vinogradov, Haresh Mani, Mariam Al-Hamad, Yvonne Fitz, Peter Q Eichacker.   

Abstract

BACKGROUND: Disseminated intravascular coagulation (DIC) appears to be important in the pathogenesis of Bacillus anthracis infection, but its causes are unclear. Although lethal toxin (LT) and edema toxin (ET) could contribute, B. anthracis cell wall peptidoglycan (PGN), not the toxins, stimulates inflammatory responses associated with DIC. METHODS AND
RESULTS: To better understand the pathogenesis of DIC during anthrax, we compared the effects of 24-hour infusions of PGN, LT, ET, or diluent (control) on coagulation measures 6, 24, or 48 hours after infusion initiation in 135 rats. No control recipient died. Lethality rates (approximately 30%) did not differ among PGN, LT, and ET recipients (P = .78). Thirty-three of 35 deaths (94%) occurred between 6 and 24 hours after the start of challenge. Among challenge components, PGN most consistently altered coagulation measures. Compared with control at 6 hours, PGN decreased platelet and fibrinogen levels and increased prothrombin and activated partial thromboplastin times and tissue factor, tissue factor pathway inhibitor, protein C, plasminogen activator inhibitor (PAI), and thrombin-antithrombin complex levels, whereas LT and ET only decreased the fibrinogen level or increased the PAI level (P ≤ .05). Nearly all effects associated with PGN infusion significantly differed from changes associated with toxin infusion (P ≤ .05 for all comparisons except for PAI level).
CONCLUSION: DIC during B. anthracis infection may be related more to components such as PGN than to LT or ET.

Entities:  

Keywords:  Bacillus anthracis; anthrax infection; coagulopathy; disseminated intravascular coagulation; edema toxin; lethal toxin; peptidoglycan; sepsis; thrombocytopenia

Mesh:

Substances:

Year:  2013        PMID: 23737601      PMCID: PMC3749004          DOI: 10.1093/infdis/jit247

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock.

Authors:  Mark S Klempner; Elizabeth A Talbot; Susanna I Lee; Sherif Zaki; Mary Jane Ferraro
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

2.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Anthrax toxins: a weapon to systematically dismantle the host immune defenses.

Authors:  Jean-Nicolas Tournier; Silvia Rossi Paccani; Anne Quesnel-Hellmann; Cosima T Baldari
Journal:  Mol Aspects Med       Date:  2009-06-26

Review 4.  Inhalational anthrax and bioterrorism.

Authors:  Richard Quintiliani; Richard Quintiliani
Journal:  Curr Opin Pulm Med       Date:  2003-05       Impact factor: 3.155

Review 5.  Pathology of inhalational anthrax animal models.

Authors:  N A Twenhafel
Journal:  Vet Pathol       Date:  2010-07-23       Impact factor: 2.221

6.  Isolation and purification of cell wall polysaccharide of Bacillus anthracis (delta Sterne).

Authors:  F S Ekwunife; J Singh; K G Taylor; R J Doyle
Journal:  FEMS Microbiol Lett       Date:  1991-08-15       Impact factor: 2.742

Review 7.  Systematic review: a century of inhalational anthrax cases from 1900 to 2005.

Authors:  Jon-Erik C Holty; Dena M Bravata; Hau Liu; Richard A Olshen; Kathryn M McDonald; Douglas K Owens
Journal:  Ann Intern Med       Date:  2006-02-21       Impact factor: 25.391

8.  Staphylococcal peptidoglycan initiates an inflammatory response and procoagulant activity in human vascular endothelial cells: a comparison with highly purified lipoteichoic acid and TSST-1.

Authors:  Eva Mattsson; Ruth Heying; Joke S van de Gevel; Thomas Hartung; Henry Beekhuizen
Journal:  FEMS Immunol Med Microbiol       Date:  2007-11-20

9.  Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers.

Authors:  Martha Triantafilou; Ahmed Uddin; Sebastien Maher; Nicholas Charalambous; Thomas S C Hamm; Ahmad Alsumaiti; Kathy Triantafilou
Journal:  Cell Microbiol       Date:  2007-07-26       Impact factor: 3.715

10.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  18 in total

1.  Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.

Authors:  Der-Shan Sun; Po-Chien Lee; Jyh-Hwa Kau; Yung-Luen Shih; Hsin-Hsien Huang; Chen-Ru Li; Chin-Cheng Lee; Yu-Ping Wu; Kuo-Ching Chen; Hsin-Hou Chang
Journal:  Virulence       Date:  2015-04-23       Impact factor: 5.882

2.  Monocyte procoagulant responses to anthrax peptidoglycan are reinforced by proinflammatory cytokine signaling.

Authors:  Narcis Ioan Popescu; Alanson Girton; Tarea Burgett; Kessa Lovelady; K Mark Coggeshall
Journal:  Blood Adv       Date:  2019-08-27

3.  Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model.

Authors:  Dharmvir S Jaswal; Xizhong Cui; Parizad Torabi-Parizi; Lernik Ohanjanian; Hannish Sampath-Kumar; Yvonne Fitz; Yan Li; Wanying Xu; Peter Q Eichacker
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

4.  B. anthracis edema toxin increases cAMP levels and inhibits phenylephrine-stimulated contraction in a rat aortic ring model.

Authors:  Yan Li; Xizhong Cui; Steven B Solomon; Kenneth Remy; Yvonne Fitz; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

5.  Nitric oxide production contributes to Bacillus anthracis edema toxin-associated arterial hypotension and lethality: ex vivo and in vivo studies in the rat.

Authors:  Yan Li; Xizhong Cui; Wanying Xu; Lernik Ohanjanian; Hanish Sampath-Kumar; Dante Suffredini; Mahtab Moayeri; Stephen Leppla; Yvonne Fitz; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-22       Impact factor: 4.733

Review 6.  Molecular determinants for a cardiovascular collapse in anthrax.

Authors:  Jurgen Brojatsch; Arturo Casadevall; David L Goldman
Journal:  Front Biosci (Elite Ed)       Date:  2014-01-01

7.  Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons.

Authors:  Ravi Shankar Keshari; Narcis Ioan Popescu; Robert Silasi; Girija Regmi; Cristina Lupu; Joe H Simmons; Alonso Ricardo; K Mark Coggeshall; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

8.  Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways.

Authors:  Narcis I Popescu; Robert Silasi; Ravi S Keshari; Alanson Girton; Tarea Burgett; Sacha S Zeerleder; David Gailani; Andras Gruber; Florea Lupu; K Mark Coggeshall
Journal:  Blood       Date:  2018-06-19       Impact factor: 25.476

9.  Confirmed Bacillus anthracis infection among persons who inject drugs, Scotland, 2009-2010.

Authors:  Malcolm Booth; Lindsay Donaldson; Xizhong Cui; Junfeng Sun; Stephen Cole; Susan Dailsey; Andrew Hart; Neil Johns; Paul McConnell; Tina McLennan; Benjamin Parcell; Henry Robb; Benjamin Shippey; Malcolm Sim; Charles Wallis; Peter Q Eichacker
Journal:  Emerg Infect Dis       Date:  2014-09       Impact factor: 6.883

Review 10.  B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components.

Authors:  Kenneth E Remy; Ping Qiu; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  BMC Med       Date:  2013-10-09       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.